STOCK TITAN
  1. Home
  2. News
  3. IVVD

Invivyd Inc - IVVD STOCK NEWS

IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
covid-19
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
clinical trial covid-19
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd to Participate at the Jefferies Healthcare Conference
conferences
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
earnings
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
conferences earnings
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
conferences
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
clinical trial covid-19
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
management
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19
clinical trial covid-19
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
earnings
Stock IVVD logo
Invivyd Inc

Nasdaq:IVVD

IVVD Rankings

#4563 Ranked by Market Cap
#4901 Ranked by Stock Gains
N/A Ranked by Dividends

IVVD Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Waltham

About IVVD

adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.